On the mechanism of the persistent action of salmeterol: what is the current position?

被引:26
作者
Coleman, R. A.
机构
关键词
salmeterol; formoterol; long-acting; beta(2)-adrenoceptor agonist; mechanism; microkinetic; exosite; receptor rebinding; BETA-ADRENOCEPTOR AGONISTS; DURATION;
D O I
10.1111/j.1476-5381.2009.00370.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The mechanism of the long duration of action of salmeterol at beta(2)-adrenoceptors has long been a matter of debate, and is still unresolved. Szczuka and colleagues have both summarized the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Much of the literature data that they have drawn upon appears contradictory, and mathematical models are inevitably flawed by the questionable validity of key values applied to them. Although the issue will undoubtedly eventually be resolved, it will probably require investigators to apply carefully designed studies on simple experimental systems such as isolated membranes or cultured cells. Only then should studies be extended to more complex systems such as isolated preparations of airways smooth muscle, where tissue bulk inevitably presents a complicating factor, particularly where relatively lipophilic compounds are concerned. British Journal of Pharmacology (2009) 158, 180-182; doi:10.1111/j.1476-5381.2009.00370.x
引用
收藏
页码:180 / 182
页数:3
相关论文
共 9 条
[1]   WHY ARE LONG-ACTING BETA-ADRENOCEPTOR AGONISTS LONG-ACTING [J].
ANDERSON, GP ;
LINDEN, A ;
RABE, KF .
EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (03) :569-578
[2]   QSAR and the rational design of long-acting dual D2-receptor/β2-adrenoceptor agonists [J].
Austin, RP ;
Barton, P ;
Bonnert, RV ;
Brown, RC ;
Cage, PA ;
Cheshire, DR ;
Davis, AM ;
Dougall, IG ;
Ince, F ;
Pairaudeau, G ;
Young, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (15) :3210-3220
[3]   In vitro and in vivo pharmacological characterization of 5-[(R)2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action [J].
Battram, C ;
Charlton, SJ ;
Cuenoud, B ;
Dowling, MR ;
Fairhurst, RA ;
Farr, D ;
Fozard, JR ;
Leighton-Davies, JR ;
Lewis, CA ;
McEvoy, L ;
Turner, RJ ;
Trifilieff, A .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) :762-770
[4]   Extent of salmeterol-mediated reassertion of relaxation in guineapig trachea pretreated with aliphatic side chain structural analogues [J].
Bergendal, A ;
Linden, A ;
Skoogh, BE ;
Gerspacher, M ;
Anderson, GP ;
Lofdahl, CG .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 117 (06) :1009-1015
[5]  
Coleman RA, 1996, TRENDS PHARMACOL SCI, V17, P324, DOI 10.1016/S0165-6147(96)10040-7
[6]   A WAY OF LOOKING AT AGONISM AND ANTAGONISM - LESSONS FROM SALBUTAMOL, SALMETEROL AND OTHER BETA-ADRENOCEPTOR AGONISTS [J].
JACK, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (05) :501-514
[7]  
RHODES DG, 1992, MOL PHARMACOL, V42, P596
[8]   Molecular mechanisms for the persistent bronchodilatory effect of the β2-adrenoceptor agonist salmeterol [J].
Szczuka, A. ;
Wennerberg, M. ;
Packeu, A. ;
Vauquelin, G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 158 (01) :183-194
[9]  
Teschemacher A, 1999, J PHARMACOL EXP THER, V288, P1084